Therapy for acute hepatitis C

被引:26
作者
Hoofnagle, JH [1 ]
机构
[1] NIDDKD, Bethesda, MD 20817 USA
关键词
D O I
10.1056/NEJM200111153452013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1495 / 1497
页数:4
相关论文
共 15 条
[1]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[2]  
[Anonymous], 1997, HEPATOLOGY, V26, pS2
[3]   The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States [J].
Armstrong, GL ;
Alter, MJ ;
McQuillan, GM ;
Margolis, HS .
HEPATOLOGY, 2000, 31 (03) :777-782
[4]   Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence [J].
Cerny, A ;
Chisari, FV .
HEPATOLOGY, 1999, 30 (03) :595-601
[5]  
Di Bisceglie Adrian M., 1998, Hepatology, V28, P1161, DOI 10.1002/hep.510280436
[6]   Pegylated (40 kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin:: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study [J].
Fried, MW ;
Shiffman, ML ;
Reddy, RK ;
Smith, C ;
Marino, G ;
Goncales, F ;
Haeussinger, D ;
Diago, M ;
Carosi, G ;
Zarski, JP ;
Hoffman, J ;
Yu, J .
GASTROENTEROLOGY, 2001, 120 (05) :A55-A55
[7]  
HOOFNAGLE JH, 2000, HEPATITIS C BIOMEDIC, P71
[8]   Treatment of acute hepatitis C with interferon alfa-2b [J].
Jaeckel, E ;
Cornberg, M ;
Wedemeyer, H ;
Santantonio, T ;
Mayer, J ;
Zankel, M ;
Pastore, G ;
Dietrich, M ;
Trautwein, C ;
Manns, MP .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (20) :1452-1457
[9]   Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin [J].
Kenny-Walsh, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (16) :1228-1233
[10]  
Liang T. Jake, 2000, Annals of Internal Medicine, V132, P296